Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases like ulcerative colitis. Read the pre-IPO report here.
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
We recently published a list of 12 Stocks That Could Split in the Near Future. In this article, we are going to take a look ...
We recently published a list of Jim Cramer Discussed These 18 Stocks As Inflation Dropped. In this article, we are going to ...
The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...
Kenvue isn't growing as quickly as Eli Lilly or Zoetis, but it offers investors a strong starting point for dividend income.
The living-history museum in Fishers is making plans for a larger exhibit that is expected to open in 2029 and better tell ...
SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start ...
A larger body doesn’t necessarily mean you have ‘clinical obesity’, according to a proposed new definition of the disease.
As the J.P. Morgan Healthcare Conference enters its second day, we're tracking presentations from GSK, Novartis, Sanofi, Eli ...
Carrie Underwood Speaks Out About Performing At Trump's Inauguration | Billboard News ...
The phrase Make America Great Again doesn’t have to divide us. Let’s reframe it as a challenge to rise to our potential — a ...